Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights

	Related Links


	Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase III, Phase II

Natural history/Epidemiology, Treatment

Active

16 and over

Pharmaceutical / Industry

CA184-025
NCT00162123

Trial Description

Summary

The purpose of this study is to evaluate the continued use of ipilimumab in patients who had clinical benefit in a prior/parent study and are now eligible to receive either Re-Induction at the time of disease progression or to continue Maintenance treatment. In addition, this study will also continue to follow patients that have had ipilimumab but who are not eligible for Maintenance or Re-Induction therapy.

Eligibility Criteria

Inclusion Criteria:

Diagnosis of advanced melanoma

Prior treatment in a prior/parent ipilimumab study

Men and women >=18 years of age (or, >=16, if allowable per local regulatory authority)

Exclusion Criteria:

Prior treatment with a CD137 agonist or CTLA-4 inhibitor or agonist, except for ipilimumab

Primary ocular or mucosal melanoma

Trial Contact Information

Trial Lead Organizations/Sponsors

Bristol-Myers Squibb Company - New York

Bristol-Myers Squibb

Study Director

For participation information at a USA site use a phone number below. For site information outside the USA please email:
		Email: Clinical.Trials@bms.com

First line of email MUST contain NCT# & Site#. Only trial sites that are recruiting have contact information at this time.

Trial Sites

U.S.A.

Arizona

Tucson

Arizona Cancer Center at University of Arizona Health Sciences Center

Lee D. Cranmer Iii, Site 082

California

Los Angeles

Angeles Clinic and Research Institute - Los Angeles

Steven J O'Day, Site 087 Ph: 310-582-7900

Argentina

Buenos Aires

Local Institution

Site 176

Germany

Berlin

Local Institution

Site 065

Sweden

Lund

Local Institution

Site 029

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00162123
Information obtained from ClinicalTrials.gov on January 07, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.